Drug intelligence / Profile preview

S-Apomorphine

Development stage: Preclinical
Lead developer: Supernus Pharmaceuticals
Modality: Small Molecules
Administration: Subcutaneous

Overview

S-Apomorphine is an enantiomer of apomorphine that is devoid of dopamine receptor agonist activity. It possesses antioxidative and iron-chelating properties. Studies have investigated its neuroprotective effects, particularly in models of Parkinson's disease, suggesting its actions are linked to its antioxidative activity, iron chelation, potential monoamine oxidase inhibition, and upregulation of tyrosine hydroxylase activity.

Other names: S-APO

Targets

LIP (Labile iron pool)KEAP1 (Kelch-like ECH-associated protein 1)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)MAOB (Monoamine oxidase B)DRD5 (Dopamine D5 Receptor)MAOA (Monoamine oxidase A)DRD1 (Dopamine D1 Receptor)

Beyond the preview

Go deeper on S-Apomorphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-Apomorphine.

Explore the full profile